Statement Of Cash Flows [Abstract]

Innate Pharma - Filing #2813423

Concept	As at 2022-12-31	2022-01-01 to 2022-12-31	As at 2021-12-31	2021-01-01 to 2021-12-31	As at 2020-12-31
Statement of cash flows [abstract]
Cash flows from (used in) operating activities [abstract]
Cash flows from (used in) operating activities	—	19 154 EUR	—	58 457 EUR	—
Cash flows from (used in) investing activities [abstract]
Proceeds from sales of property, plant and equipment, classified as investing activities	—	— EUR	—	7,000 EUR	—
Purchase of property, plant and equipment, classified as investing activities	—	535,000 EUR	—	929,000 EUR	—
Purchase of intangible assets, classified as investing activities	—	587,000 EUR	—	401,000 EUR	—
Proceeds from sales of other long-term assets, classified as investing activities	—	— EUR	—	40,000 EUR	—
Purchase of other long-term assets, classified as investing activities	—	1,000 EUR	—	1,000 EUR	—
Interest received, classified as investing activities	—	— EUR	—	367,000 EUR	—
Cash flows from (used in) investing activities	—	1 877 EUR	—	917,000 EUR	—
Cash flows from (used in) financing activities [abstract]
Proceeds from issuing shares	—	198,000 EUR	—	499,000 EUR	—
Proceeds from borrowings, classified as financing activities	—	— EUR	—	28 700 EUR	—
Interest paid, classified as financing activities	—	— EUR	—	312,000 EUR	—
Cash flows from (used in) financing activities	—	1 828 EUR	—	26 818 EUR	—
Effect of exchange rate changes on cash and cash equivalents [abstract]
Effect of exchange rate changes on cash and cash equivalents	—	428,000 EUR	—	483,000 EUR	—
Increase (decrease) in cash and cash equivalents after effect of exchange rate changes	—	19 531 EUR	—	33 037 EUR	—
Cash and cash equivalents	84 225 EUR	—	103 756 EUR	—	136 792 EUR